参考文献/References:
[1]. Pijls NHan Gelder B,van der Voort P,et al.Fractional flow reserve: a useful index to evaluate the influence of an epicardial coronary stenosis on myocardial blood flow[J].Circulation.1995,92(11):3183-3193.
[2]. Shaw LJ,Berman DS,Maron DJ,et al.Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: Results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy[J]. Circulation,2008,117(10):1283-1291.
[3].[3] Tonino PA, de Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med,2009,360(3):213-224.
[4].[4] de Bruyne B, Pijls N, Kalesan B,et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary artery disease[J]. N Engl J Med,2012,367(11):991-1001.
[5]. Tonino PA, de Bruyne B, Pijls NH, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention[J]. N Engl J Med,2009,360(3):213-224.
[6]. Pijls NH, Fearon WF, Tonino PA, et al. Fractional flow reserve versus angiography for guiding percutaneous coronary intervention in patients with multivessel coronary artery disease: 2-year follow-up of the FAME (Fractional Flow Reserve Versus Angiography for Multivessel Evaluation) study[J]. J Am Coll Cardiol,2010,56(3):177-184.
[7]. Fearon WF, Bornschein B, Tonino PA, et al. Economic evaluation of fractional flow reserve-guided percutaneous coronary intervention in patients with multivessel disease[J]. Circulation,2010,122(24):2545-2550.
[8].[8] Neumann FJ, Sousa-Uva M, Ahlsson A, et al. 2018 ESC/EACTS Guidelines on myocardial revascularization[J]. Kardiol Pol,2018,76(12):1585-1664.
[9].[9] Toth GG, Toth B, Johnson NP, et al. Revascularization decisions in patients with stable angina and intermediate lesions: results of the international survey on interventional strategy[J]. Circ Cardiovasc Interv,2014,7(6):751-759.
[10].[10] Koo BK, Yang HM, Doh JH, et al. Optimal intravascular ultrasound criteria and their accuracy for defining the functional significance of intermediate coronary stenoses of different locations[J]. JACC Cardiovasc Interv,2011,4(7):803-811.
[11].[11] D’Ascenzo F, Barbero U, Cerrato E, et al. Accuracy of intravascular ultrasound and optical coherence tomography in identifying functionally significant coronary stenosis according to vessel diameter: a meta-analysis of 2,581 patients and 2,807 lesions[J]. Am Heart J, 2015,169(5):663-673.
[12].[12] Topol EJ, Nissen SE. Our preoccupation with coronary luminology. The dissociation between clinical and angiographic findings in ischemic heart disease[J]. Circulation, 1995,92(8):2333-2342.
[13].[13] Fearon WF. Assessing intermediate coronary lesions: more than meets the eye[J]. Circulation,2013,128(24):2551-2553.
[14].[14] Gonzalo N, Escaned J, Alfonso F, et al. Morphometric assessment of coronary stenosis relevance with optical coherence tomography: a comparison with fractional flow reserve and intravascular ultrasound[J]. J Am Coll Cardiol,2012,59(12):1080-1089.
[15].[15] Jang JS, Shin HC, Bae JS, et al. Diagnostic performance of intravascular ultrasound-derived minimal lumen area to predict functionally significant non-left main coronary artery disease: a meta-analysis[J]. Korean Circ J,2016,46(5):622-631.
[16].[16] Biasco L, Pedersen F, L?nborg J, et al. Angiographic characteristics of intermediate stenosis of the left anterior descending artery for determination of lesion significance as identified by fractional flow reserve[J]. Am J Cardiol,2015,115(11):1475-1480.
[17].[17] Yang HM, Tahk SJ, Lim HS, et al. Relationship between intravascular ultrasound parameters and fractional flow reserve in intermediate coronary artery stenosis of left anterior descending artery: intravascular ultrasound volumetric analysis[J]. Catheter Cardiovasc Interv,2014,83(3):386-394.
[18].[18] Jin XJ, Tahk SJ, Yang HM, et al. The relationship between intravascular ultrasound-derived percent total atheroma volume and fractional flow reserve in the intermediate stenosis of proximal or middle left anterior descending coronary artery[J]. Int J Cardiol,2015,185:56-61.
[19].[19] Yoon MH, Tahk SJ, Lim HS, et al. Myocardial mass contributes to the discrepancy between anatomic stenosis severity assessed by intravascular ultrasound and fractional flow reserve in intermediate lesions of the coronary artery[J]. Catheter Cardiovasc Interv,2018,91(2):182-191.
[20].[20] Nahser PJ Jr, Brown RE, Oskarsson H, et al. Maximal coronary flow reserve and metabolic coronary vasodilation in patients with diabetes mellitus[J]. Circulation,1995,91(3):635-640.
[21].[21] Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation[J]. Circulation,1998,97(3):230-233.
[22].[22] Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part I: aging arteries: a “set up” for vascular disease[J]. Circulation, 2003,107(1):139-146.
[23].[23] Lakatta EG, Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease[J]. Circulation, 2003,107(1):346-354.
[24].[24] Echavarría-Pinto M, van de Hoef TP, Serruys PW, et al. Facing the complexity of ischaemic heart disease with intracoronary pressure and flow measurements: beyond fractional flow reserve interrogation of the coronary circulation[J]. Curr Opin Cardiol,2014,29(6):564-570.
[25].[25] Spaan JA, Piek JJ, Hoffman JI, et al. Physiological basis of clinically used coronary hemodynamic indices[J]. Circulation,2006,113(3):446-455.
[26].[26] Pijls NH, van Son JA, Kirkeeide RL, et al. Experimental basis of determining maximum coronary, myocardial, and collateral blood flow by pressure measurements for assessing functional stenosis severity before and after percutaneous transluminal coronary angioplasty[J]. Circulation,1993,87(4):1354-1367.
[27].[27] Fearon WF. Percutaneous coronary intervention should be guided by fractional flow reserve measurement[J]. Circulation,2014,129(18):1860-1870.
[28].[28] Uren NG, Crake T, Lefroy DC, et al. Reduced coronary vasodilator function in infarcted and normal myocardium after myocardial infarction[J]. N Engl J Med,1994,331(4):222-227.
[29].[29] Seo KW, Lim HS, Yoon MH, et al. The impact of microvascular resistance on the discordance between anatomical and functional evaluations of intermediate coronary disease[J]. EuroIntervention, 2017,13(2):e185-e192.
[30].[30] de Bruyne B, Pijls NH, Kalesan B, et al. Fractional flow reserve-guided PCI versus medical therapy in stable coronary disease[J]. N Engl J Med,2012,367(11):991-1001.
[31].[31] Lee JM, Jung JH, Hwang D, et al. Coronary flow reserve and microcirculatory resistance in patients with intermediate coronary stenosis[J]. J Am Coll Cardiol,2016,67(10):1158-1169.
[32].[32] Nam CW, Mangiacapra F, Entjes R, et al. Functional SYNTAX score for risk assessment in multivessel coronary artery disease[J]. J Am Coll Cardiol,2011,58(12):1211-1218.
[33].[33] Zimmermann FM,de Bruyne B2,?Pijls NH,et al.Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserveguided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease[J]. Am Heart J,2015,170(4):619-626.
相似文献/References:
[1]杜钧,佘强.冠心病抗炎治疗的临床研究进展[J].心血管病学进展,2016,(1):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
DU Jun,SHE Qiang.Clinical Research Progress of Anti-inflammatory Therapy of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):32.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.009]
[2]努热曼古丽·阿布都克热木,马依彤.重度左心室收缩功能不全的冠心病患者血运重建治疗疗效及预后的评价[J].心血管病学进展,2016,(1):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
NUREMANGULI·Abudukeremu,MA Yitong.Evaluation of Efficacy and Prognosis of Revascularization Therapy on Patients
with Coronary Heart Disease and Severe Left Ventricular Systolic Dysfunction[J].Advances in Cardiovascular Diseases,2016,(5):46.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.012]
[3]刘洋,综述,伍贵富,等.增强型体外反搏治疗冠心病的新机制[J].心血管病学进展,2016,(2):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
LIU Yang,WU Guifu.New Mechanism of Enhanced External Counterpulsation for
Treatment of Coronary Artery Disease[J].Advances in Cardiovascular Diseases,2016,(5):185.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.023]
[4]杨洋,综述,沈比先,等.心脏核磁共振评估缺血性心脏病的应用价值[J].心血管病学进展,2016,(2):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
YANG Yang,SHEN Bixian.Value of Cardiac Magnetic Resonance Assessment of Ischemic Heart Disease[J].Advances in Cardiovascular Diseases,2016,(5):204.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.028]
[5]史敬,综述,马依彤,等.n-3多不饱和脂肪酸对心血管疾病的临床应用[J].心血管病学进展,2016,(3):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
SHI Jing,MA Yitong.Effects of n-3 Polyunsaturated Fatty Acids on Cardiovascular Disease[J].Advances in Cardiovascular Diseases,2016,(5):278.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.016]
[6]高柳,袁晋青.重复支架置入术治疗药物洗脱支架再狭窄的研究进展[J].心血管病学进展,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
GAO Liu,YUAN Jingqing.Progress in Treatment for Drug-eluting Stent Restenosis by
Re-implementation of Stents[J].Advances in Cardiovascular Diseases,2015,(5):555.[doi:10.3969/j.issn.1004-3934.2015.05.008]
[7]邓文政,邓平.MG53蛋白的研究进展[J].心血管病学进展,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
DENG Wenzheng,DENG Ping.Research Progress of MG53[J].Advances in Cardiovascular Diseases,2015,(5):626.[doi:10.3969/j.issn.1004-3934.2015.05.027]
[8]陈静,李兴德.冠心病患者服药依从性的研究进展[J].心血管病学进展,2015,(6):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
CHEN Jing,LI Xingde.Advances in Medication Adherence of Patients with Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2015,(5):728.[doi:10.3969/j.issn.1004-3934.2015.06.018]
[9]姚雯,毛露,孙硕,等.心源性外泌体作为冠心病标志物和新靶点展望[J].心血管病学进展,2019,(6):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
YAO Wen,MAO Lu,SUN Shuo,et al.Exogenous Exosome as A New Marker and Target of Coronary Heart Disease[J].Advances in Cardiovascular Diseases,2019,(5):844.[doi:10.16806/j.cnki.issn.1004-3934.2019.06.002]
[10]郭彩艳 靳春荣.腺苷药物在心血管疾病诊治中的应用进展[J].心血管病学进展,2019,(7):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]
GUO CaiyanJIN Chunrong.Progress in the Application of Adenosine Drugs in the Diagnosis and Treatment of Cardiovascular Diseases[J].Advances in Cardiovascular Diseases,2019,(5):1011.[doi:10.16806/j.cnki.issn.1004-3934.2019.07.012]